Lee HW, et al. - A systematic review and Bayesian network meta-analysis (NMA) of 219 trials comprising of 228,710 people was conducted in order to contrast exacerbation, mortality, and adverse events among all regular inhaled drug classes, such as inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting beta-agonist (LABA), LAMA/LABA, ICS/LABA, LAMA, LABA, ICS, and placebo. In this NMA, for decreasing total exacerbations and all-cause mortality, ICS/LAMA/LABA was the most efficient treatment. In comparison with placebo, ICS/LABA also decreased all-cause mortality. All drug classes decreased the exacerbation risk in contrast to the placebo. Findings imply that for stable COPD people, triple therapy could possibly be the best choice in terms of decreasing exacerbation and all-cause mortality.